Fiscal Year:
2001
Title:
Synthetic Substitutes of Surgical Gut Sutures
Agency:
HHS
Contract:
N/A
Award Amount:
$100,000.00
Abstract:
DESCRIPTION (provided by applicant): Prior to introduction of polyglycolide
(PG) as braided synthetic absorbable sutures, surgical gut suture (SGS) was the
choice suture for many surgical procedures. Although the PG suture was a strong
competitor to SGS, the latter remained desirable in specific procedures because
of its pseudo-monofilamentous form, knot security, and absorption profile. Even
after introducing several monofilament sutures over the past two decades, the
use of SGS was slightly affected. This is because of the fast absorption
profile of SGS in comparison to all synthetic monofilament sutures. However,
new concerns about bovine spongiform encephalopathy (BSE) and its relevance to
the use of SGS and its undesirable high tissue reactions threaten its clinical
viability. This justified exploring the development of a new synthetic
absorbable suture that displays most attributes of SGS without contending with
its unwanted tissue reaction and risk of BSE. Phase I objective is to determine
feasibility of developing an absorbable, compliant monofilament suture having
(1) similar handling and knot properties to SGS; (2) an initial holding
strength superior to SGS; and (3) considerably faster absorption profile than
present monofilament sutures. Phase I plans entail (1) designing a new class of
block copolyesters based on a unique form of prepolymers and
preparation/characterization of candidate copolymers, (2) monofilament spinning
of selected copolymers and evaluating their in vitro properties as absorbable
sutures; (3) identifying two most promising candidate sutures and evaluating
their in vivo strength retention profiles and tissue reaction; and (4)
preparing Phase II plans, which will include process development and scale-up
of a selected suture and initiating needed studies to meet FDA regulatory
requirements.
PROPOSED COMMERCIAL APPLICATION:
Successful completion of Phase I will (1) provide the basic data for development of a clinically
equivalent or superior substitute to surgical gut in Phase II; (2) demonstrate the viability of using
a novel concept in macromolecular chain design to develop new absorbable materials for
known and new applications; and (3) yield new critical data pertinent to the novel use of low-
dose radiation sterilization and autocatalysis in producing absorbable surgical implants and
scaffolds for tissue engineering.
Principal Investigator:
Shalaby W. Shalaby
Small Business Information at Submission:
POLY-MED, INC.
6309 HWY 187 ANDERSON, SC 29625
EIN/Tax ID:
570981494
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned:
No
Minority-Owned:
No
HUBZone-Owned:
No